NASDAQ:TBPH

Theravance Biopharma (TBPH) Stock Price, News & Analysis

Theravance Biopharma logo
$17.03 0.00 (0.00%)
As of 11/6/2026

About Theravance Biopharma Stock (NASDAQ:TBPH)

Advanced

Key Stats

Today's Range
$17.03
▼
$17.03
50-Day Range
$17.01
▼
$17.06
52-Week Range
$13.08
▼
$21.03
Volume
N/A
Average Volume
680,323 shs
Market Capitalization
$884.18 million
P/E Ratio
16.86
Dividend Yield
N/A
Price Target
$19.00
Consensus Rating
Hold

Company Overview

Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for the maintenance of chronic obstructive pulmonary disease (COPD) in adults. In the United States, the product is commercialized through a collaboration with Viatris.

The company was established as an independent business following its separation from Theravance, Inc. in 2014. Its research and development work has included therapies for respiratory and other serious conditions.

Theravance Biopharma is led by Chief Executive Officer Rick E. Winningham.

AI Generated. May Contain Errors.

Theravance Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

TBPH MarketRank™: 
1.54825026511 of 5 stars

Theravance Biopharma scored higher than 31% of companies evaluated by MarketBeat, and ranked 764th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Theravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and no sell ratings.

  • Upside Potential

    Theravance Biopharma has a consensus price target of $19.00, representing about 11.6% upside from its current price of $17.03.

  • Amount of Analyst Coverage

    Theravance Biopharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Theravance Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Theravance Biopharma are expected to decrease by -48.08% in the coming year, from $1.56 to $0.81 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Theravance Biopharma is 16.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.15.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Theravance Biopharma is 16.86, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.34.

  • Price to Book Value per Share Ratio

    Theravance Biopharma has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for TBPH.
  • Dividend Yield

    Theravance Biopharma does not currently pay a dividend.

  • Dividend Growth

    Theravance Biopharma does not have a long track record of dividend growth.

  • News Sentiment

    Theravance Biopharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Theravance Biopharma this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $226,737.00 in company stock.

  • Percentage Held by Insiders

    7.65% of the stock of Theravance Biopharma is held by insiders.

  • Percentage Held by Institutions

    99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Theravance Biopharma's insider trading history.
Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TBPH Stock News Headlines

Theravance Biopharma (TBPH) Set to Release Earnings on Tuesday
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow
See More Headlines

TBPH Stock Analysis - Frequently Asked Questions

Theravance Biopharma's stock was trading at $18.71 at the beginning of the year. Since then, TBPH stock has decreased by 9.0% and is now trading at $17.03.

Theravance Biopharma, Inc. (NASDAQ:TBPH) announced its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by $0.18. The biopharmaceutical company earned $20.73 million during the quarter, compared to analysts' expectations of $22.49 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 0.77% and a net margin of 51.58%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Salesforce (CRM), NIO (NIO), ACADIA Pharmaceuticals (ACAD), JD.com (JD) and Micron Technology (MU).

Company Calendar

Last Earnings
8/10/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
CIK
1583107
Fax
N/A
Employees
110
Year Founded
1996

Price Target and Rating

High Price Target
$27.00
Low Price Target
$15.00
Potential Upside/Downside
+11.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.01
Trailing P/E Ratio
16.86
Forward P/E Ratio
21.02
P/E Growth
N/A
Net Income
$105.89 million
Net Margins
51.58%
Pretax Margin
56.48%
Return on Equity
-0.77%
Return on Assets
-0.46%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.54
Quick Ratio
13.54

Sales & Book Value

Annual Sales
$104.31 million
Price / Sales
8.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.86 per share
Price / Book
2.91

Miscellaneous

Outstanding Shares
51,919,000
Free Float
47,947,000
Market Cap
$884.18 million
Optionable
Optionable
Beta
0.25

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:TBPH) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners